Halozyme Therapeutics | HALO - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.58B 354M 2026-03
Baxter International USD 728M 33M 2026-03
Cara Therapeutics USD 2.19M 2.45M 2025-09
Cytokinetics USD 104.9M 13.17M 2026-03
DBV Technologies USD 3.63M 3.18M 2025-09
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 151M 21M 2026-03
MannKind USD 54.08M 4.33M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
United Therapeutics USD 156.6M 34M 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12